FFAR2 and diabetic kidney disease: Studies indicated that SCFAs could activate free fatty acid receptor 2 (FFAR2, also called GPR43) and protein kinase B (PKB, more often called AKT) signaling to improve muscular atrophy in mice of diabetic nephropathy model (Huang et al., 2020; Tang et al., 2022).